Login to Your Account

Other News To Note

Wednesday, April 17, 2013
• Innate Pharma SA, of Marseille, France, reported preclinical data for two of its programs. For its IPH33 program, it reported that humanized anti-TLR3 antibodies showed efficient blocking of TLR3 signaling with high potency.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription